In a recent legal development, Myovant Sciences Ltd. and Sumitomo Pharma America Inc. triumphed in a lawsuit that alleged the companies misled investors during their merger. The accusation rested on the claim that the law firm negotiating the deal, Skadden, Arps, Slate, Meagher & Flom LLP, allegedly had unresolved conflicts of interest, a statement which the plaintiffs asserted was false.
The lawsuit was spearheaded by plaintiff Joseph Zappia, who launched the proposed class action suit. However, the US District Court for the Southern District of New York ruled that the suit failed to sufficiently present a false or misleading statement. Furthermore, the court declared that the alleged misstatements were already public knowledge when the proxy statement was circulated.
The merger timeline reveals that Myovant filed its proxy statement in January 2023 and was later acquired by Sumitovant in March 2023. The lawsuit was not set into motion until September, six months following the finalized merger. For more details about the legal developments surrounding this lawsuit, read here.
The primary grievance presented by the lawsuit revolved around allegations of negligence, arguing that the conflict of interest by the law firm should have ruled them unfit to negotiate the merger. However, the court’s ruling determined that the negligence claim was excessively conclusory and lacked substantiating evidence.
The outcome of the lawsuit delivers a significant win for Myovant and Sumitomo, providing a legal precedent for future corporate mergers. It also triggers a conversation about the role and responsibility of law firms in ensuring full transparency during merger negotiations.